Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cardiff Oncology is a clinical-stage biotechnology company focused on developing PLK1 inhibitor onvansertib for RAS-mutated cancers. The company has no commercial revenue and operates as a pure R&D entity, with its primary asset being onvansertib in Phase 1b/2 trials for KRAS-mutated metastatic colorectal cancer and metastatic castration-resistant prostate cancer. Stock value is entirely driven by clinical trial readouts, regulatory milestones, and partnership potential.
Cardiff operates as a clinical-stage biotech with no current revenue generation. The business model relies on advancing onvansertib through clinical trials to demonstrate efficacy in RAS-mutated cancers, then either partnering with larger pharma companies for commercialization (receiving upfront payments, milestones, and royalties) or pursuing independent commercialization if sufficient capital is raised. The company's value proposition centers on targeting PLK1, a cell cycle regulator overexpressed in RAS-mutated tumors, which represent approximately 30% of all cancers. Pricing power will depend entirely on clinical differentiation versus existing standards of care and competitive checkpoint inhibitors.
Clinical trial data readouts for onvansertib in KRAS-mutated mCRC and mCRPC trials - positive efficacy/safety data can drive 50-100%+ moves
Partnership announcements with major pharmaceutical companies for co-development or commercialization rights
FDA regulatory milestone achievements (IND approvals, Fast Track designation, Breakthrough Therapy designation)
Equity financing announcements and cash runway updates - dilution concerns or extended runway clarity
Competitive developments in PLK1 inhibitor space or alternative RAS-targeting therapies
Clinical trial failure risk - onvansertib may not demonstrate sufficient efficacy or acceptable safety profile in ongoing trials, rendering the asset worthless
Competitive obsolescence - rapid advancement in RAS-targeting therapies (KRAS G12C inhibitors like sotorasib, adagrasib) and combination immunotherapies may make PLK1 inhibition less differentiated
Regulatory pathway uncertainty - FDA approval requirements for RAS-mutated cancers continue evolving, potentially requiring larger/longer trials than anticipated
Capital markets access risk - biotech funding cycles are highly volatile; inability to raise capital at reasonable valuations could force asset sales or wind-down
Direct PLK1 inhibitor competition from larger pharma with deeper resources and faster development timelines
Indirect competition from combination therapies pairing checkpoint inhibitors with targeted agents showing superior efficacy in RAS-mutated populations
Partnership risk - inability to secure pharma partner may require independent commercialization beyond company's financial capacity
Cash runway depletion - with $25-30M annual burn and approximately $30-35M in cash (estimated from current ratio and market cap), company likely needs financing within 12-18 months
Equity dilution risk - future financing rounds at depressed valuations (stock down 63% YoY) will significantly dilute existing shareholders
Going concern risk - if clinical data disappoints and capital markets remain closed, company may lack resources to complete trials
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital and may delay patient enrollment if healthcare access is constrained. Biotech sector sentiment is more correlated with risk appetite than economic fundamentals.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-12+ years out for potential commercialization). Clinical-stage biotechs with no earnings are particularly sensitive to rate changes as their entire value is based on discounted terminal values. Higher rates also increase cost of capital for future financing rounds and make risk-free alternatives more attractive to investors, reducing speculative capital flows into biotech.
minimal - Company maintains strong balance sheet with 4.20x current ratio and minimal debt (0.02 D/E ratio). Credit conditions primarily affect ability to raise equity capital rather than debt financing. Tightening credit can reduce institutional appetite for speculative biotech investments.
growth - Attracts highly speculative, risk-tolerant investors seeking asymmetric returns from binary clinical trial outcomes. Typical shareholders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance. Not suitable for value or income investors given lack of earnings, dividends, or tangible book value. Momentum traders enter around data catalyst events.
high - Clinical-stage biotechs exhibit extreme volatility with 50-100%+ single-day moves around trial data releases. Stock has declined 63% over past year, demonstrating downside volatility. Beta likely exceeds 2.0 relative to broader market. Options implied volatility typically elevated (60-100%+) ahead of data readouts.
